Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Universal Ibogaine has appointed Nick Karos as CEO on an interim basis, effective immediately.
  • Mr. Karos is a seasoned financier whose career has included senior roles with several US investment banks
  • Mr. Karos remains a short-listed candidate for the permanent position
  • Universal Ibogaine is a life sciences company researching medicalized ibogaine-centred addiction care
  • Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share

Universal Ibogaine (IBO) has appointed Nick Karos as CEO on an interim basis, effective immediately. 

Mr. Karos is based in Los Angeles, USA, and is a seasoned financier. His career includes senior roles with several US investment banks and most recently as CEO of Private Trading Group, which has provided business development and capital raising services for several successful start-up ventures.

Nick Karos sat down with Caroline Egan to discuss the appointment.

“I’m very excited to work with the talented partners at UI to move towards our goal of conducting clinical trials with Health Canada. Universal Ibogaine’s goal is to transform the addiction treatment model using ibogaine as the cornerstone of our new addiction treatment protocol. Addiction is a disease that affects society like none other, and we believe our ground-breaking protocol will give patients and families a better path towards long-term recovery.”

The board will immediately begin an executive search process for selecting a new CEO. Mr. Karos remains a short-listed candidate for the permanent position.

Universal Ibogaine is a life sciences company with a mission to research and deliver medicalized ibogaine-centred addiction care.

Universal Ibogaine Inc. (IBO) opened trading at C$0.14 per share.

More From The Market Herald

" @ the Bell: TSX slips on broad losses

Futures for Canada’s main stock index slid south on Monday, led lower by financial and mining declines, while investors awaited the Bank of

" Best biotech stocks to buy in 2023

Innovation continues to drive the broader healthcare market, and the best biotech stocks are at the forefront of new developments and therapies to
The Market Herald Video

" Odd Burger (TSXV:ODD) announces Private Placement of up to CAD$1.5 Million of convertible debentures

Odd Burger Corporation is pleased to announce that it intends to complete a proposed non-brokered private placement ‎up to 1,500 unsecured convertible debentures
Algernon Pharmaceuticals Inc.

" Algernon completes Phase 1 DMT trial for brain injury treatment

Algernon’s (CSE:AGN) subsidiary, Algernon NeuroScience, has completed Phase 1 dosing of its stroke and traumatic brain injury study.